167 results about "Leiomyocyte" patented technology

The present invention relates to methods for obtaining induced smooth muscle cells (iSMCs), iSMCs, iSMCs for use in a method of treating a disease or disorder or for use in tissue engineering, and the use of skeletal muscle derived cells for obtaining iSMCs.

The invention belongs to the field of biological medicine, and particularly relates to application of deaminotyrosine in preparation of a medicine for treating vascular calcification symptoms. The invention finds that deaminotyrosine can significantly reduce the vascular calcification degree of an in-vitro cell model and an in-vivo animal model by inhibiting osteogenic differentiation and calcium salt deposition of vascular smooth muscle cells; therefore, the invention provides a new application of the deaminated tyrosine or pharmaceutically acceptable salt, ester, solvate or prodrug thereof in preparation of drugs for treating vascular calcification symptoms. The invention also provides a pharmaceutical composition, which takes deaminated tyrosine as an active component, and provides a brand new drug choice for clinical prevention and treatment of vascular calcification.

The invention discloses application of salvianolic acid A in preparation of a medicine for preventing and treating vulnerable plaques of advanced atherosclerosis. The invention also discloses application of the salvianolic acid A combined with ferulic acid or the salt thereof in preparation of drugs for preventing and treating advanced atherosclerosis vulnerable plaques. Researches find that salvianolic acid A can promote apoptosis of senescent vascular smooth muscle cells and has a Senlytics effect; the salvianolic acid A stabilizes vulnerable atherosclerotic plaques by reducing the load of senescent vascular smooth muscle cells; the salvianolic acid A is in non-covalent binding with ASP54, ALA55, LYS58, ASP93, ASP102 and LYS112 of the HSP90AA1 to play a role in inhibition, and the ASP93 has the greatest contribution to binding free energy. The research of the invention is of great significance to the development and application of drugs with anti-aging effect for stabilizing advanced atherosclerotic vulnerable plaques.

The invention discloses a functional coating, an intravascular stent and a preparation method and application of the intravascular stent. The functional coating comprises an endothelialization promoting active substance and an anti-proliferation drug; the endothelialization promoting active substance comprises at least one of polypeptide containing an RGD sequence, polypeptide containing a YIGSR sequence, polypeptide containing an REDV sequence, a beta-polypeptide polymer or a beta-polypeptide-polyester block copolymer. The functional coating disclosed by the invention can be used for surface functional modification of interventional medical devices, can selectively promote adhesion and proliferation of vascular endothelial cells at an implantation part, realizes rapid endothelialization, and can controllably release an anti-proliferation drug to inhibit excessive proliferation of vascular smooth muscle cells, so that the vascular endothelial cells are prevented from being damaged. Therefore, the risks of restenosis and advanced thrombus are effectively reduced.

The invention discloses an application of a compound Isaridin E or a pharmaceutical salt thereof in preparation of anti-vascular calcification drugs and related diseases, and relates to the technical field of medical biology. A classical high phosphate induced smooth muscle cell calcification model and an in-vivo vascular calcification model induced by a high dose of vitamin D3 are adopted, and through an in-vitro cell experiment, an in-vitro experiment and an overall animal experiment, it is found that the compound Isaridin E has a remarkable improvement effect on vascular calcification caused by calcium and phosphorus metabolism disorder. The medicine has the effects of remarkably inhibiting vascular smooth muscle cell osteogenic differentiation induced by high phosphate and vitamin D3, inhibiting vascular calcification and remarkably reducing formation of calcium-phosphorus crystals on vascular walls. The invention develops a brand new medical application of the marine compound Isaridin E, and the marine compound Isaridin E can be used for research and development of drugs for treating vascular calcification and calcification-related diseases.

The invention discloses an application of 4-octyl itaconic acid (4-OI) in preparation of a medicine for improving pulmonary arterial hypertension (PAH). In-vivo experiments show that 4-OI can significantly reduce pulmonary vascular wall thickening and collagen deposition of a PAH rat model, and effectively improve PAH and vascular remodeling. In-vitro experiments further reveal that 4-OI reduces endoplasmic reticulum stress (ERS) by inhibiting a PERK-eIF2alpha pathway, further blocks SM22 dependent smooth muscle cell phenotypic transformation and endothelial-mesenchymal transformation (EndMT) processes, finally inhibits vascular remodeling, and plays a role in treating PAH. The three key pathological processes of ERS, EndMT and vascular remodeling are closely linked, a new perspective is provided for deeply understanding the correlation among oxidative stress, endothelial dysfunction and vascular structure change in PAH, meanwhile, a theoretical foundation is laid for developing PAH and vascular remodeling accurate treatment drugs, and clinical transformation value is achieved.

The invention discloses a covered stent, which relates to the technical field of interventional medical instruments and comprises a covered stent section and bare stent sections connected to two axial ends of the covered stent section. The covered stent section comprises a stent main body in a pipe network shape and a tubular covering film covering the surface of the stent main body; the bare stent section comprises a bare stent connected to the axial end part of the covered stent section; the bare stent is formed by weaving a first metal wire in a spiral spring shape, and the stent main body is formed by weaving a second metal wire in a spiral spring shape; and the bare stent is loaded with an anti-hyperplasia drug. The bare stents are arranged at the two ends of the covered stent section, the anti-hyperplasia medicine is loaded on the bare stents, the bare stents are formed by weaving the first metal wires in the spiral spring shape, the bare stents can better conform to the inner cavity of a blood vessel, stimulation to the blood vessel is reduced, and therefore hyperplasia of smooth muscle cells of the blood vessel is reduced; the anti-hyperplasia drug can inhibit hyperplasia of vascular smooth muscle cells, and finally the situation that the two ends of the covered stent are narrow is prevented or reduced.

The invention discloses a method for detecting the influence of hypoxia on autophagy of rat pulmonary artery smooth muscle cells, and relates to the field of medicine. Comprising the following steps: cell culture: selecting rats in different oxygen states, and separating and culturing pulmonary artery smooth muscle cells through a tissue adherence method; detection: carrying out the following detection on the smooth muscle cells: WB detection of autophagy and ferroptosis related proteins; performing ELISA (enzyme-linked immunosorbent assay) detection on related markers; carrying out qPCR detection on mRNA related to autophagy and ferroptosis; cell autophagy detection; carrying out ROS detection in the cells; and detecting ferrous ions in cells. According to the invention, rat pulmonary artery smooth muscle cells in different oxygen states are respectively subjected to autophagy and ferroptosis related protein detection, related marker detection, autophagy and ferroptosis related mRNA detection, cell autophagy detection, intracellular ROS detection and intracellular ferrous ion detection, so that the influence of autophagy on ferroptosis can be effectively proved; and the blank of medical technology is filled.

The invention discloses application of gynostemma pentaphyllum polysaccharide to prevention of vascular wall thickening caused by space microgravity and a medicine, the gynostemma pentaphyllum polysaccharide is applied to prevention of vascular wall thickening caused by space microgravity and the medicine for prevention of vascular wall thickening caused by space microgravity, and the medicine contains the gynostemma pentaphyllum polysaccharide; the gynostemma pentaphyllum polysaccharide reduces thickening of blood vessel walls by inhibiting proliferation and migration of vascular smooth muscle cells, can be used for preventing or treating aorta blood vessel wall thickening caused by space microgravity, and is suitable for health guarantee of astronauts in long-term space missions.

The present disclosure relates to endoplasmic reticulum protein HYOU1-binding compounds for inhibiting endoplasmic reticulum-mitochondrial interactions and uses thereof.The features and advantages of the present disclosure may be summarized as follows:(a) The present disclosure provides a compound that can bind to the endoplasmic reticulum protein HYOU1 and inhibit endoplasmic reticulum-mitochondrial interactions increased by oxLDL (oxidized low-density lipoprotein).(b) The present disclosure provides a composition capable of preventing, ameliorating or treating autophagy disorder-related diseases, particularly arteriosclerosis or pulmonary hypertension, which contains the above-described compound as an active ingredient.(c) Since the composition of the present disclosure reduces intracellular lipids by inducing autophagy in atherosclerosis-induced tissues, it can be useful used in the amelioration or treatment of atherosclerosis.(d) Since the composition of the present disclosure reduces smooth muscle cell proliferation by inducing autophagy in smooth muscle cells in which contraction is induced by TGF-β, it can be usefully used in the amelioration or treatment of pulmonary arterial hypertension.

The present invention provides a vascular smooth muscle cell-tropic capsid which has an enhanced rate of infection to a vascular smooth muscle.　The present invention provides a capsid of an adeno-associated virus, the capsid being characterized in that a factor of tropism for vascular smooth muscle cells is added thereto. The factor of tropism is a peptide that is presented on the surface of a virus particle.　The peptide includes any one of "RENKLGE", "KDTVPRE", "TETGKTA", "STPAAKE", "RNREPTE", "ARNGTTE", "KDTAERQ", "NRGGNQD", "NRPDTNS", and "TRATSQE" in cases where vascular smooth muscle cells of a mouse (Mus musculus) are to be infected. The peptide includes any one of "NRPETNP", "SHDPSKE", "SEIRRDQ", "NRNKHEE", "RQDNKME", "THPPAPQ", "TRGGGSE", "TEKQTNS", "RVTMGSE", and "ATKNQNE" in cases where vascular smooth muscle cells of human (Homo sapiens) are to be infected.

The invention belongs to the technical field of artery stents, and particularly relates to a degradable coronary artery stent and a preparation method thereof. Wherein the degradable coronary stent is of a tubular network structure prepared by a main frame and connecting rib components, the main frame is of an open network structure, anchoring points are arranged at nodes, and the connecting rib components are detachably connected and lock the main frame through the anchoring points to form an integral rigid structure, so that the elastic retraction force after a blood vessel is implanted is effectively resisted; the connecting rib component is gradually degraded and loses the locking capacity along with the promotion of vascular repair, the loaded rapamycin is synchronously released, smooth muscle cells with active proliferation are accurately inhibited, the risk of restenosis in the stent is reduced, meanwhile, the activity of the main framework is recovered, the main framework slightly deforms along with vascular pulsation, and vascular intimal injury and inflammatory response are reduced.

The invention relates to the field of antibodies, in particular to a monoclonal antibody for treating overactive bladder and application of the monoclonal antibody. The monoclonal antibody specifically recognizes and is combined with an adrenergic receptor beta3 (ADR beta3), the monoclonal antibody is obtained through a hybridoma technology, and the M13 monoclonal antibody with high affinity is successfully screened out. The M13 antibody promotes the increase of cAMP concentration in smooth muscle cells and activates a PKA pathway by activating an ADR beta3 receptor, thereby promoting the relaxation of bladder smooth muscles, increasing the bladder capacity and reducing the non-autonomous contraction of detrusor muscles. Animal experiments prove that the M13 monoclonal antibody can effectively improve the urination frequency and urine volume of a mouse OAB model, and has a good clinical application prospect. The monoclonal antibody and the preparation method thereof can be widely applied to the field of treatment of overactive bladder.

The application relates to the application of lycorine hydrochloride in the preparation of a medicine for inhibiting the proliferation of a neointimal in a blood vessel. Lycorine hydrochloride has the effect of inhibiting the proliferation of a neointimal in a blood vessel, and the effect is mainly realized by inhibiting the proliferation and migration of vascular smooth muscle cells. In the body, the results show that lycorine hydrochloride can significantly inhibit the intimal proliferation caused by left common carotid artery ligation, and in vitro experiments prove that lycorine hydrochloride can intervene in the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB. Lycorine hydrochloride inhibits the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB, and the proliferation of a neointimal in a blood vessel through a MAPKs signal path. The application provides data for preparing lycorine hydrochloride into a medicine for inhibiting the proliferation of a neointimal in a blood vessel, and is expected to be applied to the prevention and treatment of complications after percutaneous coronary intervention, such as restenosis or in-stent thrombosis, and can become a potential medicine for intervening in restenosis.

The invention relates to the technical field of biomedical materials. The invention discloses a Schiff base-sulfonated hyaluronic acid light-cured microsphere as well as a preparation method and application thereof. The microspheres are prepared by condensing DL-lysine and paeonol to generate Schiff base, then conjugating the Schiff base with sulfonated hyaluronic acid through a carbodiimide chemical method, and finally molding by adopting a microfluidic technology and carrying out ultraviolet curing. The metal chelation characteristic of Schiff base is combined with the precise structure regulation advantage of the microspheres, and the prepared microspheres show an excellent synergistic effect when applied to the surfaces of implant materials such as degradable magnesium alloy, iron alloy and zinc alloy: the corrosion resistance of a base material can be remarkably improved, an effective protective layer is formed, and the service life of the microspheres is prolonged. Meanwhile, the compound has multiple biological functions of promoting endothelial cell proliferation, inhibiting excessive proliferation of smooth muscle cells and regulating and controlling macrophages to be polarized to anti-inflammatory phenotypes, and has a wide application prospect in the biomedical fields of intravascular stents, bone fixing instruments and the like.

An artificial tissue tube having a stem cell-derived smooth muscle layer and an endothelial cell layer is produced. Compared with conventional methods, it is possible to produce an artificial tissue tube that produces physiological contraction and relaxation reactions by using at least three times of stem cell-derived smooth muscle cells and further using stem cell-derived endothelial cells to produce an artificial tissue tube. An artificial blood vessel produced using an iPS cell derived from a patient with Viller's syndrome is shown to be an artificial blood vessel reflecting a pathological condition, and therefore an artificial tissue tube reflecting a pathological condition of a plurality of diseases can be produced using the iPS cell. The artificial tissue tube can be used for screening and transplanting medicines.

The invention discloses a composite medicine coating for treating pulmonary arterial hypertension, and belongs to the technical field of medical instruments. The coating is composed of an inert protective layer and a composite drug coating, the inert protective layer is a polyamino acid polymer, responds to pH change and is rapidly disintegrated only in the pH environment of a target site, and the loss of the composite drug coating in the delivery process is reduced; the composite drug coating is a composite component containing two or more gene regulatory factors and / or drugs, achieves a synergistic effect through a signal path, cells and a gene level, more efficiently regulates pulmonary artery endothelial cell dysfunction and smooth muscle cell injury, and has precise targeting and irreplaceability.

The invention discloses application of icariin in preparation of drugs for preventing and treating chronic kidney disease mineral substances and bone metabolism disorders. Relates to the technical field of medicine. The invention provides an application of icariin as an active pharmaceutical ingredient in preparation of a CKD-MBD treatment drug. Pharmacological experiments show that icariin can improve renal fibrosis, inhibit hyperparathyroidism, correct calcium and phosphorus metabolism, regulate and control bone metabolism related molecular expression, inhibit transdifferentiation of vascular smooth muscle cells to bone cells, inhibit vascular calcification and correct bone metabolism disorder, so that CKD-MBD is effectively prevented and treated. When icariin is used for preventing or treating CKD-MBD, the icariin is clear in component, exact in curative effect and low in side effect, and has a wide medical application prospect.

The invention relates to application of harmine in preparation of a medicine for preventing and treating vascular calcification. The harmine can be used for preventing and / or treating vascular calcification. Experiments show that harmine reduces osteogenic differentiation of vascular smooth muscle cells by down-regulating expression of RUNX2 and BMP2 and up-regulating expression of alpha-SMA at the same time, calcium salt deposition of blood vessels can be reduced, and it is indicated that harmine has a remarkable inhibition effect on vascular calcification. The new application of harmine in the anti-vascular calcification aspect is confirmed, so that the research of harmine in the technical field of medicines can be expanded, a new way is provided for research and development of drugs for treating vascular calcification, and a new theoretical direction is provided for clinical application.

The invention provides a functional nerve conduit modified by a smooth muscle extracellular matrix as well as a preparation method and application of the functional nerve conduit, and belongs to the field of biological tissue materials. Smooth muscle cells are inoculated to the surface of a material, the functional nerve conduit is prepared through smooth muscle cell-derived extracellular matrix modification, the nerve conduit remarkably promotes dorsal root ganglion and PC12 axon regeneration, angiogenesis is promoted by inducing Schwann cell migration and VEGF secretion, a guiding bridge is provided for new axon, and the nerve conduit has the advantages that the nerve conduit has a good application prospect. The cut-off nerve is reconnected, the large-segment defective sciatic nerve is repaired, the function control and the muscle function after nerve regeneration are improved, and good application prospects are achieved.

The invention belongs to the technical field of gene engineering and cardiovascular disease treatment, and particularly discloses application of an expression inhibitor of a TSPAN4 gene in preparation of a medicine for treating cardiovascular diseases and the medicine containing the expression inhibitor of the TSPAN4 gene. According to the application disclosed by the invention, firstly, a carotid artery injury mouse model is constructed, and research finds that after expression deletion of TSPAN4, the TSPAN4 has a remarkable improvement effect on intimal neogenesis; according to the present invention, the expression of the TSPAN4 gene is further inhibited by using the siRNA interfering RNA technology of the targeting TSPAN4 gene, such that the phenotype of the smooth muscle cell can be changed after the treatment with the human h-siTSPAN4 so as to achieve the cardiovascular disease treatment purpose; according to the method, expression of the TSPAN4 gene can be inhibited by delivering siRNA, so that proliferation and migration of abnormal smooth muscle cells are inhibited, and development of cardiovascular diseases is reduced.

The invention discloses a BCAT2 gene, a BCAT2 inhibitor and application, belongs to biomedical application, and provides application of the BCAT2 gene as a target spot in screening of drugs for preventing, relieving and / or treating diabetes-related diseases. The invention further provides application of the BCAT2 inhibitor in preparation or screening of drugs for preventing, relieving and / or treating diabetes-related diseases. It is found that by inhibiting expression of BCAT2, phenotype transdifferentiation of vascular smooth muscle cells can be remarkably inhibited, and then the progress of diabetes mellitus plaque internal calcification is inhibited, and by taking the gene as a target spot, innovative drugs for treating diabetes mellitus plaque internal calcification by aiming at the gene and related molecules thereof can be designed; it is further verified through experiments that after the BCAT2 inhibitor inhibits BCAT2 gene expression, the progress of diabetes related diseases can be effectively relieved, a new thought and prospect are provided for future drug development, and remarkable social value and market value are achieved.

The present application relates to the application of delta-Viniferin in the preparation of drugs for preventing or treating metabolic cardiovascular diseases. Delta-Viniferin can inhibit the expression level of aging and inflammation related genes / proteins of vascular endothelial cells, reduce endothelial dysfunction, and clarify its anti-hypertensive effect. Delta-Viniferin can inhibit the expression level of vascular smooth muscle cell phenotype conversion related genes / proteins, improve the contraction function of vascular smooth muscle, and significantly alleviate the degradation of elastic fibers of the vascular wall and the rupture of the intima of the aortic wall in vivo, and clarify its effect on preventing and treating aortic dissection. Delta-Viniferin can inhibit the expression level of myocardial fibroblast fibrosis related genes / proteins, and clarify its anti-myocardial fibrosis effect. Delta-Viniferin can promote white adipose tissue browning by targeting the SIRT1-FOXO1 axis, increase energy consumption, and clarify its effect on resisting obesity. In summary, the compound delta-Viniferin has the effect of protecting various metabolic cardiovascular diseases, and can be used to prepare drugs for preventing and treating metabolic cardiovascular diseases.

The invention provides application of a mucolipoprotein transient receptor potential channel 1 as a target spot in preparation of a medicine for treating pulmonary arterial hypertension, and belongs to the technical field of biological medicine manufacturing. The invention relates to application of a mucolipoprotein transient receptor potential channel 1 (TRRP Mucipin1, TRPML1) as a target spot in preparation, development or screening of a medicine for treating pulmonary hypertension (PH), in particular to application of the medicine in preparation, development or screening of the medicine for treating the PH. The invention also provides application of a reagent 1 for up-regulating smooth muscle cell Mcoln1 gene and / or smooth muscle cell TRPML1 protein expression or a reagent 2 for improving smooth muscle cell TRPML1 protein activity in preparation of drugs for treating PH. Experiments show that the over-expressed TRPML1 in the smooth muscle affects the PH pulmonary vascular remodeling process and PH generation and development through autophagy regulation and control, and the purpose of PH treatment is achieved.

The invention relates to the technical field of molecular biology and medicine, and particularly discloses application of WWP1 in preparation of a medicine for preventing and / or treating aortic dissection, and relates to application of WWP1 in prevention and treatment of aortic dissection. Molecular biology experiment detection of the expression level of the WWP1 in aortic dissection aortic tissue and the expression level of smooth muscle cell contraction and secretion phenotype marker genes proves that the expression level of the WWP1 in an aortic dissection aortic tissue sample is obviously higher than that of a control aortic tissue; and overexpression of the WWP1 in an animal model significantly reduces the morbidity of the aortic dissection and improves the contraction phenotype of the aortic smooth muscle, i.e., the protectiveness of the WWP1 in the morbidity process of the aortic dissection is improved. Based on the research result, the WWP1 can be used as a drug target for screening, preventing and treating the aortic dissection.

The present invention relates to a method for obtaining an induced smooth muscle cell (iSMC), iSMC, iSMC for use in a method for treating a disease or condition or in tissue engineering, and the use of a skeletal muscle-derived cell for obtaining iSMC.

The present invention relates to a pharmaceutical composition containing Cbfβ (Core-binding factor subunit beta) expressing vascular smooth muscle cells or a culture fluid thereof as an active ingredient for the prevention or treatment of age-related diseases. It has been found that inhibition of Cbfβ expression in vascular smooth muscle cells promotes vascular calcification and osteoclast differentiation and that the culture fluid of Cbfβ-expressing vascular smooth muscle cells inhibits osteoclast differentiation. Thus, the composition can be advantageously utilized as a pharmaceutical composition for the prevention, treatment, alleviation, or diagnosis of age-related diseases.

Described herein is a panel of three or four miRNAs that can be used to transdifferentiate vascular smooth muscle cells or fibroblasts into endothelial cells. As demonstrated herein, miR-143-3p and / or miR-145-5p inhibitors coupled with miR-5 146a-5p and miR-18lb-5p mimics were sufficient for accomplishing this transformation. This transdifferentiation protocol can be used to generate inducible endothelial cells that are transcriptionally, phenotypically, and functionally similar to other endothelial cells. This miRNA-engineered approach is useful in a range of cardiovascular-based therapies. In some embodiments, the methods use a 4-miRNA consisting of miR-143-3p and / or miR-145-Sp inhibitors, and miR-146a-5p and miR-181b-5p mimics, to produce iECs from SMCs or fibroblasts. In some embodiments, the SMC are isolated from aorta, coronary artery, pulmonary artery, umbilical artery, bladder smooth muscle cells, or derived from adipose tissue smooth muscle cells or progenitors, or blood derived circulating smooth muscle cell progenitors.

The invention discloses a multifunctional intravascular stent for diabetics and a preparation method of the multifunctional intravascular stent, and relates to the technical field of cardiovascular interventional therapy instruments. The polycitrate is used as a carrier on the surface of the intravascular stent body to form the drug-loaded slow-release coating, and the drug-loaded slow-release coating has high antioxidant content, can provide oxidative stress attenuation continuously for a long time, provides a good microenvironment for cell tissue recovery, and promotes regeneration and repair of blood vessels. The biological immunosuppressor and the diabetes specific drug are loaded in the drug-loaded slow-release coating, the biological immunosuppressor is a drug having an excellent effect on common patients, the diabetes specific drug is a drug having a specific effect on diabetic patients, and the two drugs have a synergistic effect, so that the effect of treating diabetes is achieved; the coating on the surface of the intravascular stent has the effects of resisting inflammation, improving endothelial dysfunction and inhibiting proliferation and migration of smooth muscle cells aiming at diabetic patients so as to promote regeneration and repair of diseased blood vessels of the diabetic patients.